URINARY BLADDER NEOPLASMS

This study tests whether adding immunotherapy drugs (nivolumab with or without BMS-986205) to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. About 855 adults who are eligi…

This study tests whether a combination of two drugs, durvalumab and olaparib, can help control advanced bladder cancer in people who cannot receive standard platinum-based chemotherapy. About 154 participants with stage IV bladder cancer that cannot be removed by surgery will rec…

This study tests a combination of two drugs (TAR-200 and cetrelimab) in people with muscle-invasive bladder cancer who are scheduled for bladder removal surgery but cannot or choose not to receive standard chemotherapy beforehand. The goal is to see if the drug combination can el…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants who are not having their bladder removed wil…

This study tests two experimental treatments—TAR-200 (a drug placed directly into the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in 220 people with high-risk bladder cancer that came back after BCG therapy. Participants cannot or choose not to have th…

This early-phase study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has certain genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is …

This study tests whether a combination of two drugs (TAR-200 and cetrelimab) can help people with a serious type of bladder cancer live longer without their cancer getting worse, compared to standard chemotherapy plus radiation. Participants are those who cannot or choose not to …

This study looks at whether newer PET/MRI scans (FAPI and FDG) are better than standard MRI at diagnosing muscle-invasive bladder cancer and predicting how well pre-surgery treatment works. About 80 participants will be scanned before and after therapy. The goal is to help doctor…

This study looks at whether a urine test called BladMetrix can reliably detect bladder cancer recurrence in 500 adults with non-muscle invasive bladder cancer. Participants provide extra urine samples during routine follow-up visits over two years. The goal is to see if this test…